Drug intelligence / Profile preview

KFP-H009

Development stage: Unknown
Lead developer: Carephar
Modality: Small Molecules

Overview

KFP-H009 is a small molecule drug candidate being developed by Nanjing Carephar Pharmaceutical for the treatment of peptic ulcers. As of 2021, the asset is in Phase 1 clinical development. Nanjing Carephar Pharmaceutical has a strategic focus on gastrointestinal and cardiovascular diseases, with a portfolio that includes both marketed products like vonoprazan and other pipeline candidates such as KFP-H008. While the specific biological target of KFP-H009 has not been publicly disclosed, it represents an early-stage expansion of the company's acid-related disease franchise.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on KFP-H009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KFP-H009.

Explore the full profile